Werewolf Therapeutics Q2 EPS $0.08 Beats $(0.29) Estimate, Sales $21.000M
Werewolf Therapeutics Inc HOWL
$0.35
▼ -29.44%
($-0.15)
⬇️ Below Yest. Low
⚡ High Volume
🗓️ Earnings Next Week
Open
$0.50
Prev Close
$0.50
Day Range
$0.34 – $0.50
52W Range
$0.27 – $2.38
Market Cap
$17.16M
Beta
0.29
EPS (TTM)
$-1.21
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2021-04-30 |
| Shares Out. | 48,600,000 |
| Website | werewolftx.com/ ↗ |
| Phone | 16179520555 |
| Employees | 14 |
| Revenue | $21.0M |
| Gross Profit | $21.0M |
| Net Income | $3.7M |
| Total Assets | $24.2M |
| Total Liabilities | $7.9M |
| Equity | $16.3M |
About Werewolf Therapeutics Inc
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. It is leveraging the proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. It has one reportable segment, which focuses on the discovery and development of cancer therapeutics.
Werewolf Therapeutics Inc is a publicly traded company under the ticker symbol HOWL on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
10 analysts (2026-07-01)